181 related articles for article (PubMed ID: 34584860)
1. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a
An J; Yan M; Yu N; Chennamadhavuni A; Furqan M; Mott SL; Loeffler BT; Kruser T; Sita TL; Feldman L; Nguyen R; Pasquinelli M; Hanna NH; Abu Hejleh T
Transl Lung Cancer Res; 2021 Aug; 10(8):3608-3615. PubMed ID: 34584860
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
3. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
4. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
Yegya-Raman N; Friedes C; Sun L; Iocolano M; Kim KN; Doucette A; Cohen RB; Robinson KW; Levin WP; Cengel KA; Lally B; Agarwal M; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Aggarwal C; Berman AT; Langer CJ; Feigenberg SJ
Clin Lung Cancer; 2023 Jul; 24(5):474-482. PubMed ID: 37076396
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and immune phenotypes associated with
Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
8. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
10. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
13. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
Torralvo J; Friedlaender A; Achard V; Addeo A
Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer.
Peravali M; Ahn J; Chen K; Rao S; Veytsman I; Liu SV; Kim C
Oncologist; 2021 Aug; 26(8):694-700. PubMed ID: 33844354
[TBL] [Abstract][Full Text] [Related]
15. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
16. Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.
Jazieh K; Gad M; Saad A; Wei W; Pennell NA
Transl Lung Cancer Res; 2021 Jul; 10(7):3071-3078. PubMed ID: 34430348
[TBL] [Abstract][Full Text] [Related]
17. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
18. Impact of
Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
[TBL] [Abstract][Full Text] [Related]
19. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
[TBL] [Abstract][Full Text] [Related]
20. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
